Pharmaceutical formulation comprising lanthanum compounds

Details Pharmaceutical formulation comprising lanthanum compounds Pharmaceutical formulation comprising lanthanum compounds

2004-08-26

2008-12-16

Richter, Johann R (Department: 1616)

Drug, bio-affecting and body treating compositions

Inorganic active ingredient containing

C424S464000, C424S715000, C514S492000

Reexamination Certificate

active

07465465

ABSTRACT:
This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and c) compressing the resulting mixture into a tablet or filing up the resulting mixture in a appropriate container.

REFERENCES:
patent: 4822594 (1989-04-01), Gibby
patent: 4877735 (1989-10-01), Nogami et al.
patent: 5853758 (1998-12-01), Lo
patent: 5968976 (1999-10-01), Murrer et al.
patent: 6703005 (2004-03-01), Allan et al.
patent: 2001/0014352 (2001-08-01), Batra et al.
patent: 2002/0051822 (2002-05-01), Atherton et al.
patent: 2002/0122823 (2002-09-01), Bunick et al.
patent: 2002/0155168 (2002-10-01), Abrams et al.
patent: 2003/0186845 (2003-10-01), Yoshida
patent: 2004/0029829 (2004-02-01), Miyazaki et al.
patent: 2004/0043971 (2004-03-01), Mazess et al.
patent: 2004/0120922 (2004-06-01), Burke
patent: 2004/0161474 (2004-08-01), Moerck et al.
patent: 2005/0096438 (2005-05-01), Chang et al.
patent: 2005/0131138 (2005-06-01), Connor et al.
patent: 2005/0147580 (2005-07-01), Connor et al.
patent: 2005/0208080 (2005-09-01), Heightman et al.
patent: 2005/0209423 (2005-09-01), Chang et al.
patent: 2005/0220750 (2005-10-01), Robert et al.
patent: 2005/0220751 (2005-10-01), Charmot et al.
patent: 2005/0220889 (2005-10-01), Charmot et al.
patent: 2005/0220890 (2005-10-01), Charmot et al.
patent: 2005/0239901 (2005-10-01), Chang et al.
patent: 2006/0121127 (2006-06-01), Ferdinando et al.
patent: 2 216 437 (1996-10-01), None
patent: 295861 (1988-12-01), None
patent: 299910 (1989-01-01), None
patent: 1 267 662 (2001-10-01), None
patent: 1 344 528 (2003-09-01), None
patent: 0015745 (2000-08-01), None
patent: 62-145024 (1987-06-01), None
patent: 62145024 (1987-06-01), None
patent: 1085088 (1989-03-01), None
patent: 8070851 (1996-03-01), None
patent: 200247210 (2002-02-01), None
patent: 2002-187838 (2002-07-01), None
patent: 2002-193735 (2002-07-01), None
patent: 10-1997-0706684 (2002-06-01), None
patent: WO 96/30029 (1996-10-01), None
patent: WO-98/00104 (1998-01-01), None
patent: WO 99/15189 (1999-04-01), None
patent: WO-01/76409 (2001-10-01), None
patent: WO-02/00227 (2002-01-01), None
patent: WO-02/49656 (2002-06-01), None
patent: WO-02/085348 (2002-10-01), None
patent: WO-03/061624 (2003-07-01), None
patent: WO-03/094933 (2003-11-01), None
patent: WO-2004/016553 (2004-02-01), None
patent: WO-2004/037274 (2004-05-01), None
patent: WO-2004/080467 (2004-09-01), None
patent: 2005/018651 (2005-03-01), None
patent: WO-2005/041902 (2005-05-01), None
patent: WO-2005/092039 (2005-10-01), None
patent: WO-2005/097072 (2005-10-01), None
Hutchison AJ Calcitriol, lanthanum carbonate, and other new phosphate binders in the mangement of renal osteodystrophy. Perit Dial Int. 1999, 19 Suppl 2, S408-S412.
Patent Abstract of Japan abstracting Publication No. 62-145024 Jun. 29, 1987.
Marketletter Shire's Fosrenol clears bone safety hurdle Jun. 17, 2002, 1 page.
“Encyclopedia of Pharmaceutical Technology” by Swarbrick et al., vol. 2 (1990); “Biodegradable polyester polymers as drug carriers to clinical pharmacokinetics and pharmacodyanamics”; “Chewable tablets” pp. 397-417.
“Encylopedia of Pharmaceutical Technology” by Swarbrick et al., vol. 14 (1996); “Self-medication to technology transfer considerations for pharmaceuticals”; “Formulation design”, pp. 391-399.
“Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy” by A. J. Hutchison, Perit Dial Int. vol. 12, Suppl. 2, 1999, pp. S408-S412.
International Search Report for PCT/CA2004/001563 mailed Jan. 19, 2005.
Supplementary Partial European Search Report for EP 04 76 1727 completed Sep. 5, 2006.
“Fosrenol”—Retreived from the Internet at URL: http://web.archiveorg/web/20050901114025/www.fosrenol.com/presribingInfo.pdf. Sep. 11, 2005.
Chiang, S-S., et al., “Lanthanum Carbonate (Fosrenolä) Efficacy and Tolerability in the Treatment of Hyperphosphatemic Patients with End Stage Renal Disease,” Clinical Nephrology, vol. 63, No. 6, Jun. 2005, p. 461-470.
Cullel-Young, M., et al., “Lanthanum Carbonate—Treatment of Hyperphosphatemia,” Drugs of the Future, vol. 28, No. 3, Mar. 1, 2003, p. 224-228.
De Broe, et al., “Lanthanum Carbonate: A new agent in the treatment of hyperphosphataemia in end-stage renal failure”, Jun. 2002.
D'Haese et al., “A Multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients”, Kidney International 2003, 63:S73-S78.
Fukagawa, Is Lanthanum carbonate safer and more effective than calcium carbonate for hyperphosphatemia in dialysis patients? Nature Clinical Practice nephrology 2005, 1(1), 20-21.
Korean Office Action dated Oct. 11, 2007 issued for corresponding Korean Patent Application No. 10-2006-7003792. (4 pgs).
Partial Translation and Copy of book titled “the principle and technique of formulations,” as cited by Korean Examiner in Oct. 11, 2007 KR Office Action for Korean Patent Application No. 10-2006-7003792, (10 pages).
“III. Dry Granulation” and “V. Direct Compression Tabletting,” Pharmacy, Press of People's Health, Oct. 2002, selected extracts (3 pages).
Official Communication dated Apr. 4, 2008, Chinese Patent Application for Invention No. 200480031578.8.
U.S. Appl. No. 11/191,600, Ferdinando et al.
“Pharmaceutical Studies On Drug Delivery Systems For Geriatrics and Cancer Therapies”, Yoshuinbobu Fukumori et al., Research and Development of Prophylactic and Therapeutic Agents for Age-Related Diseases in Aging Society. Annual Report 2002-2003, p. 281-285.
Preparation of Lecithin Microcapsules by a Dilution Method Using the Wurster Process for Intraarterial Administration in Gadolinium Neutron Capture Therapy, K. Jono et al., Chem Pharm Bull, 1999, vol. 47, No. 1, p. 54-63.
“Design and Preparation of Ethyl Cellulose Microcapsules of Gadopentetate Dimeglumine for Neutron-Capture Therapy Using the Wurster Process”, Y. Fukumori et al., Chem Pharm Bull, 1993, vol. 41, No. 6, p. 1144-1148.
“Synthesis and FT-IR study of Ln-glucose-pyridine complexes”, L. Zheng et al., AIP Conf. Proc. (1998), vol. 430, Number: Fourier Transform Spectroscopy, pp. 324-326.
“Interaction of metal ions with D-glucose in glassy state-a FT-IR study”, Ning Xi et al., Proc. SPIE-Int. Soc. Opt. Eng., 1989, vol. 1145, Number: Int. Conf. Fourier Transform Spectrosc., 7thpp. 405-406.
“Interaction of Monosaccharides With Metal Ions—NMR Analysis Of Lanthanide Complex”, Kunihiko Izumi, Kagaku Kogyo, 1988, vol. 39, No. 11, pp, 918-924.
“Fourier transform infrared spectroscopy as a tool for the study of rare earth carbohydrate complexes”, Hong Liang et al. Mikrochim. Acta, 1988, vol. 1, No. 1-6, pp. 215-217.
NMR Studies of the interaction of metal ions with poly-(1, 4-hexuronates).V. Proton NMR spectra of methyl .alpha.-D-gluo-and methyl .beta.-Dhamamelopyranosides, 1, 6-anhydro- .beta.D-manno, 1,6-anhydro-.beta.-D-talo-and 1, 6-anhydro-.beta.-D-allopyranoses and epi-inositol, Hans Grasdalen et al., Acta Chem.Scand., Ser. A, 1978, vol. A32, No. 1, pp. 31-39.
“An analysis of NMR shifts in lanthanide complexes”, H. Bergen et. al. Aust. J Chem., 197

Affiliated with

Also associated with

Rating

Pharmaceutical formulation comprising lanthanum compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical formulation comprising lanthanum compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulation comprising lanthanum compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4044031